Targeting platelet migration in the postischemic liver by blocking protease-activated receptor 4

Area of Science:

• Hepatology
• Immunology
• Transplantation Medicine

Background:

• Platelets are crucial in hepatic ischemia/reperfusion (I/R) injury.
• Antiplatelet therapies for liver transplantation are limited by bleeding risks.
• Thrombin activates platelets and endothelial cells via protease-activated receptor 4 (PAR-4) during reperfusion.

Purpose of the Study:

• To investigate the impact of PAR-4 blockade on platelet recruitment and microvascular injury in hepatic I/R.
• To assess if PAR-4 inhibition attenuates inflammation without affecting coagulation.

Main Methods:

• C57BL/6 mice underwent hepatic I/R and were treated with a PAR-4 antagonist (TcY-NH2) or vehicle.
• Platelet and CD4 T-cell recruitment were analyzed using intravital microscopy.
• Tissue injury, regeneration, and blood coagulation were assessed.

Main Results:

• TcY-NH2 treatment reduced I/R-induced platelet and CD4 T-cell recruitment.
• PAR-4 blockade improved sinusoidal perfusion and decreased tissue injury.
• Hemostasis and liver regeneration remained unaffected.

Conclusions:

• PAR-4 is a promising therapeutic target for mitigating platelet-mediated liver injury during transplantation.
• PAR-4 blockade offers a potential strategy to reduce complications in liver I/R.